TrialThe oncologist2023

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.

Eric Van Cutsem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.